Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 4, 2010, Pages 722-729

  Paty, I ^a   Trellu, M ^a   Destors, J M ^a   Cortez, P ^a   Boelle E ^a   Sanderink, G ^a  

^a SANOFI   (France)

Author keywords

Anticoagulation; Avidin; Deep vein thrombosis; Idrabiotaparinux; Idraparinux; Reversal

Indexed keywords

AVIDIN; IDRABIOTAPARINUX; IDRAPARINUX; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ANTICOAGULATION; ARTICLE; BACKACHE; BIOTINYLATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 77952703086     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.03746.x     Document Type: Article

References (15)

1. Herbert JM, Hérault JP, Bernat A, van Amsterdam RG, Lormeau JC, Petitou M, van Boeckel C, Hoffmann P, Meuleman DG. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998, 91:4197-205.
2. Veyrat-Follet C, Vivier N, Trellu M, Dubruc C, Sanderink GJ. The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials. J Thromb Haemost 2009, 7:559-65.
3. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. J Thromb Haemost 2004, 2:47-53.
4. Bousser MG, Bouthier J, Büller HR, Cohen AT, Crijns H, Davidson BL, Halperin J, Hankey G, Levy S, Pengo V, Prandoni P, Prins MH, Tomkowski W, Torp-Pedersen C, Wyse DG. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008, 371:315-21.
5. Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, Prins MH, Raskob GE. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007, 357:1094-104.
6. Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, Prins MH, Raskob GE. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 2007, 357:1105-12.
7. Trellu M, Perez Y, Ortiz J, Cheng S, Paty I. Bioequipotency of idraparinux and biotinylated idraparinux after single dose in healthy subjects. J Thromb Haemost 2007, 5(Suppl. 2). P-T-678
8. Wilchek M, Bayer EA. Foreword and introduction to the book (strept)avidin-biotin system. Biomol Eng 1999, 16:1-4.
9. Kang YS, Saito Y, Pardridge WM. Pharmacokinetics of [3H]biotin bound to different avidin analogues. J Drug Target 1995, 3:159-65.
10. Stoldt HS, Aftab F, Chinol M, Paganelli G, Luca F, Testori A, Geraghty JG. Pretargeting strategies for radio-immunoguided tumour localisation and therapy. Eur J Cancer 1997, 33:186-92.
11. Paty I, Trellu M, Paquet N, Sibille M, Perez Y, Ortiz J. Neutralization by avidin of anticoagulant activity of biotinylated idraparinux, the first and unique reversible long-acting anticoagulant [abstract]. J Thromb Haemost 2007, 5(Suppl. 2). O-T-050
12. Savi P, Herault JP, Duchaussoy P, Millet L, Schaeffer P, Petitou M, Bono F, Herbert JM. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy. J Thromb Haemost 2008, 6:1697-706.
13. Buller HR, Destors JM, Gallus AS, Prins MH, Raskob GE. Idrabiotaparinux, a biotinylated long-acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin [abstract]. Blood 2008, 112:32.
14. Herault JP, Pasdelou MP, Remandet B, Hurbin F, Trellu M. Body distribution of idraparinux and idrabiotaparinux in rats [abstract]. J Thromb Haemost 2009, 7(Suppl. 2). PP-WE-388
15. Paty I, Pacquet N, Sibille M, Cortez P, Berard F, Nicolas JF. Immune response after first and second iv injection of avidin used as the neutralizing agent for biotinylated idraparinux [abstract]. J Thromb Haemost 2007, 5(Suppl. 2). P-T-667